Yineng Chen

Ms. Yineng Chen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
DLDaphna Landau
Daphna Landau
GLGrant T. Liu
Grant T. Liu
RARobert A. Avery
Robert A. Avery
GYGui-Shuang Ying
Gui-Shuang Ying
YCYineng Chen
Yineng Chen
WKWilliam R. Katowitz
William R. Katowitz

1 January 2025 in Arquivos Brasileiros de Oftalmologia
Verified
Journal Article
Open access
TLTaylor J. Linaburg
Taylor J. Linaburg
TPTejus Pradeep
Tejus Pradeep
BRBrian Rinelli
Brian Rinelli
YCYuanyuan Chen
Yuanyuan Chen
YCYineng Chen
Yineng Chen
MTMadhura Tamhankar
Madhura Tamhankar
This study evaluated rates of thyroid eye disease-related eyelid surgeries, strabismus surgeries, and orbital decompressions in active thyroid eye disease patients treated with teprotumumab compared to those who were not. In this single-center longitudinal study, we compared patients with active thyroid eye disease evaluated from 02/01/2017 to 01/31/2020 (pre-teprotumumab era) with those seen from 02/01/2020 to 04/30/2023 (teprotumumab era). Patients from the pre-teprotumumab era who received corticosteroids and/or orbital radiation were compared with those in the teprotumumab era treated with teprotumumab, with or without corticosteroids and/or orbital radiation. The primary outcomes were rates of orbital decompressions, strabismus surgery, and eyelid surgery among patients with at least 6 months of follow-up. Orbital decompressions involving two or more walls were classified as severe. Of 486 records reviewed, 106 patients had active thyroid eye disease. Among them, 33 were from the pre-teprotumumab era; 22 received corticosteroids and/or orbital radiation, and 11 received no treatment. Seventy three patients were from the teprotumumab era; 37 received teprotumumab (with or without corticosteroids and/or orbital radiation), 10 received corticosteroids and/or orbital radiation alone, and 26 received no treatment. Demographics were comparable between groups. Orbital decompression was performed in 11 of 44 eyes (25.0%) in the pre-teprotumumab era treated with corticosteroids and/or orbital radiation (8 one-wall, 3 ≥two-wall), compared to 3 of 74 eyes (4.1%) in the teprotumumab era treated with teprotumumab with or without corticosteroids and/or orbital radiation (all one-wall). The overall rate of orbital decompressions and the rate of ≥two-wall decompressions were significantly lower in the teprotumumab era (p=0.02 and p=0.0496, respectively). There was no significant difference in one-wall decompressions between era (p=0.07). Rates of strabismus surgeries (27.3% vs. 13.5%, p=0.19) and eyelid surgeries (22.7% vs. 21.6%, p=0.92) did not significantly differ between the era. In patients with active thyroid eye disease, treatment with teprotumumab was associated with a significantly lower rate and severity of orbital decompressions compared to treatment with corticosteroids and/or orbital radiation alone. However, the rates of strabismus and eyelid surgeries remained similar between groups.

18 February 2025 in Vision
Verified
Journal Article
Open access
PDF file
ECEllie Cheng
Ellie Cheng
KHKatherine Han
Katherine Han
YCYineng Chen
Yineng Chen
Penny AsbellPenny Asbell
Penny Asbell
GYGuishuang Ying
Guishuang Ying
TGthe DREAM Research Group
the DREAM Research Group
Purpose: To assess associations of the severity of the symptoms and signs of dry eye disease (DED) with the quality of life in patients with moderate-to-severe DED. Methods: At baseline, 6 and 12 months, participants (n = 535) were assessed for DED symptoms using the Ocular Surface Disease Index (OSDI) and signs using conjunctival staining, corneal staining, tear break-up time (TBUT), Schirmer’s testing, meibomian gland dysfunction, and tear osmolarity. Quality of life was evaluated using the Short Form Health Survey (SF-36), consisting of a Physical Component Summary (PCS) and Mental Component Summary (MCS). Spearman correlation coefficients (rho) were used to evaluate correlations between the severity of DED and the SF-36. Results: At baseline, worse DED symptoms indicated by a higher OSDI total score were correlated with worse PCS (rho = −0.13, p = 0.002) and MCS (rho = −0.09, p = 0.03) in the SF-36. Worse vision-related function was correlated with a worse PCS score (rho = −0.18, p < 0.0001), and worse ocular symptoms were correlated with a worse MCS score (rho = −0.15, p < 0.001). More severe DED signs including corneal staining (rho = −0.22, p < 0.001), Schirmer test (rho = 0.11, p = 0.01), TBUT (rho = 0.14, p < 0.001), and tear osmolarity (rho = −0.12, p = 0.02) were correlated with a worse PCS score but were not correlated with MCS score (p ≥ 0.39). ln longitudinal analysis, only the worsening of ocular symptoms was significantly correlated with the worsening of the MCS score (rho = −0.09, p = 0.04). Conclusions: In patients with moderate-to-severe DED, there were significant yet weak correlations between the severity of dry eye symptoms/signs and the physical or mental components of the SF-36. Healthcare professionals should offer patients with DED symptom relief and support for the emotional and practical challenges in their daily lives.

5 January 2026 in Hygiene and Environmental Health Advances
Verified
Journal Article
Open access
RTRandy T. Tangang
Randy T. Tangang
YCYineng Chen
Yineng Chen
JMJunrong Ma
Junrong Ma
SFSamantha Friedman
Samantha Friedman
IMImran Hossain Mithu
Imran Hossain Mithu
SLShao Lin
Shao Lin

3 July 2026 in Journal of Glaucoma
Verified
Journal Article
Open access
TSTzuriel Sapir
Tzuriel Sapir
CCChun Yin Chow
Chun Yin Chow
MHMina Halimitabrizi
Mina Halimitabrizi
YCYineng Chen
Yineng Chen
RSRebecca Salowe
Rebecca Salowe
Joan O'BrienJoan O'Brien
Joan O'Brien
Precis: Our study showed a lower occurrence of primary open angle glaucoma in African ancestry patients when taking their ancestry into consideration compared with the Cirrus HD-OCT classification. Purpose: Structural differences in the retinal nerve fiber layer (RNFL) of African ancestry individuals are underrepresented in the Cirrus HD-OCT normative database. Our prior study reclassified primary open angle glaucoma (POAG) color codes using RNFL data from healthy African ancestry controls. This study compares color-code classification between the Cirrus database and our reclassification for African ancestry POAG cases. Patients: A total of 787 eyes from the Primary Open Angle African American Glaucoma Genetics (POAAGG) study. Methods: Eyes were staged using the Enhanced Glaucoma Staging System (GSS2), and RNFL thickness color codes were reclassified based on an African ancestry-specific cohort. Results: The POAAGG reclassification model reported fewer abnormal yellow and red color codes (16.4% and 6.3%) than Cirrus (18.0% and 9.4%, P <0.001). Reclassification shifted 12.8% of red codes to yellow/green and 23.0% of yellow codes to green ( P <0.001). Among stage 1 glaucoma eyes, 19.0% of red codes and 23.1% of yellow codes shifted to greener classifications ( P =0.04). Similar patterns were seen in quadrant-specific and stage-specific analyses. Conclusions: The discrepancy in POAG color-code classification suggests that an ancestry-conscious normative database may reduce overdiagnosis in African ancestry individuals.

7 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AMAhlam Awad Mohammed
Ahlam Awad Mohammed
AAAida Abashawl
Aida Abashawl
SDSarity Dodson
Sarity Dodson
WAWondu Alemayehu
Wondu Alemayehu
AGAlemu Gemechu
Alemu Gemechu
FGFLuorometholone as Adjunctive MEdical Therapy for Trachomatous Trichiasis Surgery (FLAME) Trial Research Group
FLuorometholone as Adjunctive MEdical Therapy for Trachomatous Trichiasis Surgery (FLAME) Trial Research Group
Purpose To report the design of FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial. Design Parallel design, double-masked, placebo-controlled clinical trial with 1:1 randomization to fluorometholone 0.1% eyedrops twice daily or placebo twice daily for four weeks in eyes undergoing trachomatous trichiasis (TT) surgery; assessing the efficacy, safety, and cost-effectiveness of fluorometholone 0.1% in preventing recurrent postoperative trichiasis. Methods Up to 2500 eligible persons with trachomatous trichiasis (TT) undergoing lid rotation surgery will be enrolled in Jimma zone, Ethiopia. Participants, surgeons, study field staff, and study supervisors leading operational aspects of the trial are masked to treatment assignment. Randomization is stratified by surgeon, which simultaneously stratifies by the district. The study visits are at baseline/enrollment, at four-week post-enrollment, six months, and one year (study exit). The primary outcome is cumulative one-year postoperative TT (PTT) incidence, defined as: ≥1 lashes touching the globe, evidence of epilation, and/or repeat TT surgery. Secondary postoperative outcomes include number of trichiatic lashes, location thereof (touching the cornea or not), evidence of post-operative epilation, entropion, changes in corneal opacity, IOP elevation, need for cataract surgery, visual acuity change from baseline, eyelid contour abnormality, granuloma, eyelid closure defect, and occurrence of adverse events. Health economic analyses center on calculating the incremental cost per case of PTT avoided by fluorometholone treatment. Conclusion The FLAME Trial is designed to provide evidence of the efficacy, safety, and cost-effectiveness of adjunctive topical peri-/postoperative fluorometholone 0.1% therapy with trichiasis surgery, which is hypothesized to reduce the risk of recurrent trichiasis while being acceptably safe. Trial Registration: ClinicalTrials.gov # NCT04149210